Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
Cantor Fitzgerald
Chinese Patent Office
Daiichi Sankyo
Express Scripts
Chubb
Fish and Richardson
Covington
Novartis

Generated: October 23, 2017

DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for VIIV HLTHCARE, and when can generic versions of VIIV HLTHCARE drugs launch?

VIIV HLTHCARE has eighteen approved drugs.

There are fourteen US patents protecting VIIV HLTHCARE drugs on VIIV HLTHCARE drugs in the past three years.

There are seven hundred and fifty-two patent family members on VIIV HLTHCARE drugs in sixty-eight countries and fifty-nine supplementary protection certificates in fifteen countries.

Summary for Applicant: Viiv Hlthcare

International Patents:752
US Patents:14
Tradenames:11
Ingredients:11
NDAs:18
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
RETROVIR
zidovudine
INJECTABLE;INJECTION019951-001Feb 2, 1990APRXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Viiv Hlthcare
LEXIVA
fosamprenavir calcium
SUSPENSION;ORAL022116-001Jun 14, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Viiv Hlthcare
TRIZIVIR
abacavir sulfate; lamivudine; zidovudine
TABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-001Aug 12, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
EPIVIR
lamivudine
SOLUTION;ORAL020596-001Nov 17, 1995AARXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-001Aug 12, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
TRIUMEQ
abacavir sulfate; dolutegravir sodium; lamivudine
TABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
EPIVIR
lamivudine
SOLUTION;ORAL020596-001Nov 17, 1995AARXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
EPIVIR
lamivudine
SOLUTION;ORAL020596-001Nov 17, 1995► Subscribe► Subscribe
Viiv Hlthcare
RETROVIR
zidovudine
CAPSULE;ORAL019655-001Mar 19, 1987► Subscribe► Subscribe
Viiv Hlthcare
ZIAGEN
abacavir sulfate
TABLET;ORAL020977-001Dec 17, 1998► Subscribe► Subscribe
Viiv Hlthcare
EPZICOM
abacavir sulfate; lamivudine
TABLET;ORAL021652-001Aug 2, 2004► Subscribe► Subscribe
Viiv Hlthcare
RETROVIR
zidovudine
TABLET;ORAL020518-002Oct 4, 1996► Subscribe► Subscribe
Viiv Hlthcare
ZIAGEN
abacavir sulfate
SOLUTION;ORAL020978-001Dec 17, 1998► Subscribe► Subscribe
Viiv Hlthcare
RETROVIR
zidovudine
CAPSULE;ORAL019655-001Mar 19, 1987► Subscribe► Subscribe
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VIIV HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
abacavir sulfate, dolutegravir and lamivudine
Tablets600 mg/50 mg/300 mg
TRIUMEQ
8/14/2017
abacavir
Oral Solution20 mg/ml
ZIAGEN
12/27/2012
fosamprenavir calcium
Tablets700 mg
LEXIVA
1/18/2012
lamivudine
Oral Solution10 mg/mL
EPIVIR
11/22/2011
maraviroc
Tablets150 mg and 300 mg
SELZENTRY
8/8/2011
abacavir sulfate, lamivudine and zidovudine
Tablets300 mg/150 mg/300 mg
TRIZIVIR
3/22/2011
abacavir sulfate
Tablets300 mg
ZIAGEN
1/28/2009
lamivudine
Tablets150 mg and 300 mg
EPIVIR
10/16/2007
abacavir sulfate and lamivudine
Tablets600 mg/300 mg
EPZICOM
9/27/2007
lamivudine and zidovudine
Tablets150 mg/300 mg
COMBIVIR
6/26/2007

Non-Orange Book Patents for Viiv Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,365,587Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
7,108,864Tablet formation► Subscribe
8,188,271Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity► Subscribe
9,051,337Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrr- olo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamides► Subscribe
8,624,023Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
7,041,667CCR5 modulators► Subscribe
8,754,214Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
8,778,943Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-.alpha- .]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamides► Subscribe
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
9,273,065Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Viiv Hlthcare Drugs

Country Document Number Estimated Expiration
Japan2001525840► Subscribe
Slovenia0933372► Subscribe
Hong Kong1090836► Subscribe
Poland202845► Subscribe
South Korea20050046743► Subscribe
Hong Kong1030552► Subscribe
South Africa9811830► Subscribe
Czech Republic20010219► Subscribe
Australia739953► Subscribe
MexicoPA02011631► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/1999Austria► SubscribePRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628
2008Austria► SubscribePRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
426Luxembourg► Subscribe91426, EXPIRES: 20190712
C/GB98/019United Kingdom► SubscribePRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318
2014 00032Denmark► SubscribePRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
99C0033Belgium► SubscribePRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
4Finland► Subscribe
C016/2005Ireland► SubscribeSPC016/2005: 20060407, EXPIRES: 20191216
2008 004, C 1284974Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Novartis
Farmers Insurance
Dow
Accenture
QuintilesIMS
Boehringer Ingelheim
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot